Back

Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac device

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Arrhythmias in heart failure Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Jose Ramon Gonzalez Juanatey

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

6 More presentations in this session

Presentation thumbnail
Fusion CRT pacing and LA reverse remodeling: the key for low incidence of atrial fibrillation in HF patients
Doctor C. Vacarescu (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
Characterizing atrial fibrillation in patients with and without heart failure and across the ejection fraction spectrum: incidence, prevalence, and treatment strategies
Doctor V. Valente (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Heart failure detection from electrocardiogram using artificial intelligence
Doctor A. Ranjbar (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Change of natriuretic peptides over time predicts new development of atrial fibrillation in at risk population
Doctor C. Powell (Cork, IE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation burden characteristics in heart failure patients with reduced versus preserved ejection fraction as detected by insertable cardiac monitors.
Mr S. Sarkar (Moundsview, US)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias in heart failure
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
When to consider device therapy in HFrEF - discussion
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources